THE SCOPE

Vol. 19, No. 1, Winter 2003

The Society of Toxicologic Pathology Annual Meeting

The Human Genome: Implications for Toxicologic Pathology and Carcinogenesis



The 2003 STP Annual Meeting will be held in Savannah, Georgia at the International Trade & Convention Center June 15–19. The theme for the meeting is "The Human Genome: Implications for Toxicologic Pathology and Carcinogenesis." There will be four full days with six scientific sessions and one day with two continuing education courses. In addition to premier research being presented, attendees will have the opportunity to network. The meeting schedule allows plenty of time for attendees to network before, during and after sessions. The STP Annual Meeting has low registration fees, provides high-quality scientific presentations, top-quality abstracts and the opportunity to view new products and services in the exhibit hall. A listing of the topics and session speakers is available on pages 4-5.

SAVANNAH, GEORGIA — HOST CITY FOR 2003 ANNUAL MEETING

Join the Society of Toxicologic Pathology in this beautiful, historic city and explore the past while learning about future scientific breakthroughs and new technologies.

Founded in 1733, Savannah has been a host city since its inception. The city has welcomed domestic and international visitors from Civil War times to 1996, when Savannah hosted the Summer Olympics sailing competitions.

General James Edward Oglethorpe developed the city to be the capital of Georgia, America's 13th Colony. Amazingly, Oglethorpe's design of regularly spaced public squares, and open green space in an urban setting has largely survived the ensuing two and half centuries, setting Savannah apart from many cities of similar size.

Savannah has more than 2,400 architecturally and historically significant buildings in a 2.5 square mile Historical District.The historic waterfront district, once the center of cotton commerce, is again the center of life in Savannah. There is history and beauty, both man-made and natural, from Fort Pulaski to Tybee Island and Savannah, to the azalea lined Victory Drive, to the commanding view from atop the Tybee Lighthouse, the oldest on the Atlantic coastline.

INSIDE

FROM THE PRESIDENT

"The toxicologic pathologist shortage: Can money solve this problem?"

In the last issue of *The Scope* (Vol. 18:3, Summer, 2002) I acknowledged what seems pretty obvious — there is an acute shortage of trained toxicologic pathologists. Estimates presented in a joint STP-ACVP survey suggest the shortage at numbers between 50 and 70 pathologists currently. Based on the current number of students in residency/graduate training programs, the potential supply will not keep up with demand (and retirements) over the next 5 or more years. Not only is the shortage acute, it is going to get worse.

What are some of the practical ramifications of the current shortage? Well, full employment for current pathologists is a given. Salaries are "highly competitive." Opportunities for movement and advancement are great. This is very beneficial for current pathologists. And yet virtually every pathologist I have talked to recently says they are "really busy — you know: too busy." Many folks feel overwhelmed, and there is little that compensation can do when work starts/continues eating into personal time. The demands of the profession are becoming unmanageable for some. This is a significant downside of the current shortage.

continued on page 2

MEMBERSHIP DUES

Thank you for paying your 2003 Membership Dues. The advancement of STP's vision, mission, and goals is made possible by your membership dues as well as by organizational contributions to the Society. Please encourage your organization to support the STP.

Information about Organizational Membership is available from STP Headquarters. Contact Clarissa Wilson at (703) 438-7508.

If you haven't already paid your 2003 Membership Dues, please visit the STP Web site at **www.toxpath.org**.

NEW MEMBERS

Denise Bounous .....*AstraZeneca Pharmaceuticals LP*
Fernando Capela e Silva .....*University of Evora*
Siegrid Damsch .....*Johnson & Johnson Pharm. Research & Dev. A Division of Janssen Pharmaceutical N.V.*
Lisa Domico.....*Rutgers, State University of New Jersey*
Gordon Flake .....*National Institute of Environmental Health Sciences*
Rodney Frank .....*3M Pharmaceuticals*
Satoh Hiroshi .....*Daiichi Pharmaceutical Co., Ltd.*
Kiyoshi Imai.....*Biosafety Research Center*
Glenn Kantor .....*Pharmacia Corporation*
Ramon Kemp .....*Merck Research Laboratories*
Andres Kreite.....*Tissue Informatics Inc.*
M. Gerard O'Sullivan .....*3M Pharmaceuticals*
Michael Ringenberg .....*Merck & Co*
Mark Rolsma .....*Pfizer Global Research and Development*
Hiroyuki Tsuda.....*National Cancer Center Research Institute*
Katharine Whitney .....*Huntingdon Life Sciences*
Ingrid Pruimboom-Brees .....*Pfizer- Drug Safety Technology Center*
Holly Jordan .....*GlaxoSmithKline*
Dai Nakae.....*Sasaki Institute, Sasaki Foundation*
Aaron Sargeant .....*The Ohio State University*

STP Newsletter
Society of Toxicologic Pathology

Lynda Lanning, Senior Editor
(240) 683-3378 (MD)
lyndal@otsuka.com

Carol Thompson, Editor
(518) 846-6225 (NY)
thompsc1@wyeth.com

Clarissa Russell Wilson, Executive Director
(703) 438-7508 (VA)
STP Headquarters
1767 Business Center Drive, Suite 302
Reston, VA 20190-5332
http://www.toxpath.org
stphq@toxpath.org

Send newsletter material to STP Headquarters at the address above, or by Fax to (703) 438-3113.

The Society of Toxicologic Pathology Newsletter (ISSN #10761535) is published 3 times a year by the Society of Toxicologic Pathology, c/o AIM, 1767 Business Center Dr., Suite 302, Reston, VA 20190-5332. Membership dues include $5.00 for the cost of publication. Send address changes to STP Newsletter, AIM, 1767 Business Center Dr., Suite 302, Reston, VA 20190-5332.

www.toxpath.org

FROM THE PRESIDENT

continued from page 1

We are in a classic situation of supply and demand. The demand for trained toxicologic pathologists will remain high, not decrease. Unfortunately, the supply is not keeping up with it. In my opinion, the single most important factor that is affecting supply is that potential trainees (i.e., veterinary students) do not know about or consider pathology/toxicologic pathology as a viable career choice.

I think most of us got into pathology because it was fascinating. Figuring out disease causes and mechanisms was both intellectually challenging and stimulating. Plenty of us ran around doing "High Fives" after diagnosing a difficult lesion and deciding what it meant. Being a pathologist wanna-be was "cool"!

Are we reaching today's students with the message that pathology is a great career choice? Probably not. The number of pathologists in academia has steadily dwindled in the past ten years. Many of our mentors have retired or soon will. Academic salaries are not even close to being competitive with those in the private sector, and many new graduates of pathology training programs opt for work in industry or with the government. Vacancies in academia go unfilled, and a residually smaller number of pathologists in academia struggle to meet demands of teaching, diagnostic service support and research. More demands on fewer academic pathologists translates into less student contact time. Less contact time means less time to get out the message that "Pathology is cool!

Although academic pathologists are busier than ever, they are also less visible. Reductions in state and federal funding of academic institutions has forced many

continued on page 3

FROM THE PRESIDENT

continued from page 2

"Departments of Pathology" to become folded into basic science departments (in my institution its the "Department of Biomedical Sciences and Pathobiology"). Clearly, the unique identity of pathology is being lost. Not many students discern that "a pathobiologist" is really a pathologist and very few will encounter a toxicologic pathologist during their vet school careers. Consequently, fewer students even understand what pathologists are and do, and most opt for more understandable career choices such as practice. This comes full circle—less visibility, less student career demand, and then more academic positions are allocated to practice oriented disciplines. Vacant pathology positions (because they can't be filled due to non-competitive salaries and the pathologist shortage) get scavenged by administrators caught in budget freezes and reallocation demands.

The loss of academic pathology positions means even fewer mentors for the next generation of pathologists. Training pathologists is time intensive. Some academic institutions realize they don't have the critical mass of faculty to deliver a viable training program and these programs have folded or will fold. I think we can all appreciate the consequences of this potential death-spiral. We are experiencing them right now.



So, what should we do? Can money solve the problem? A couple of suggestions follow, just to stimulate thought and to get you to pick up the phone and call me (540) 231-4643 or send e-mail (drbob@vt.edu):

We each need to push the concept that "Pathology is cool!" (This doesn't cost anything, but is crucial.)

We need to take steps to ensure the continued viability of academic pathology and training programs. (This takes money and politicking.) (and NO, I am not being self-serving!)

We need to intensively recruit students into pathology early in their veterinary school experience by providing mentoring, pathology-based learning opportunities, and meaningful financial support. (This essentially requires people and money.)

We have to realize this may take a decade or more to accomplish. (This takes patience and determination.)

Thanks for reading! Next time — "How do we hook the students who will become the next generation of pathologists?"

Postscript: Last month I got a call from Ted Slone at MPI. They are supporting a resident through the entire 3-year training program at Michigan State. MPI 'adopted' their local pathology residency-training program in hopes of increasing the supply by providing training experiences and money. Many other companies are dedicated, long-term donors that support STP efforts to provide financial aid for pathology trainees. Money won't solve all the problems, but it sure is going to help!

John Robertson V.M.D. Ph.D.

VA-MD Regional College of
Veterinary Medicine
Blacksburg, VA 24061
(540) 231-7666

INTERNET COMMITTEE

Revision of the STP Web site home page is complete and the Internet Committee welcomes comments from the STP membership on this new look. Staff at AIM are in the process of combining and standardizing the membership databases to provide more efficient and usable information to the membership. This includes providing a secure Internet connection to allow for online payment of STP dues via our Web site. In addition, you can register for the Annual Meeting and printout the agenda for the meeting at http://eshow2000.com/STP/.

The Society Privacy Policy will restrict the publication of membership information to the Members Only section of the Web site.

SCIENTIFIC AND REGULATORY POLICY COMMITTEE (SRPC) REPORT

The mission of this committee is to provide the STP executive council (EC) and STP membership with perspective on the scientific and regulatory issues that are pivotal to the practice of toxicologic pathology. The following is a list of current committees and their activities.

"Best Practices Guidelines" is with the FDA's Center for Veterinary Medicine for comments.

The neuropathology subcommittee document has been reviewed by the EPA and they have provided comments.

The ovary evaluation subcommittee, with the goal of assessing the state of knowledge in the histopathologic evaluation of the ovary, and to review the use of special methods such as morphometry as screening tools for ovarian toxicity. A draft document is being prepared.

The hyperplasia subcommittee has been formed with the objective of addressing the use and interpretation of this term as well as to describe its relationship to the development of neoplasia. A draft document is expected for general comment by early 2003.

The subcommittee on electronic data entry is addressing issues in the areas of histopathology, necropsy, clinical

continued on page 6

STP Annual Meeting June 15–19, 2003
Savannah, Georgia

General Sessions June 15 – 19, 2003

The 22nd Annual Meeting of the Society of Toxicologic Pathology topic is "The Human Genome: Implications for Toxicologic Pathology and Carcinogenesis." There will be six sessions covering areas of comparative genetics/genomics and pathology of cancer including animal models of cancer and bioassays for predicting carcinogenicity in humans, aspects of the molecular pathology of cancer and toxicity, the use of biomarkers, and mechanisms of cancer pathogenesis in risk assessment and cancer treatment.

Continuing Education Courses Sunday, June 15, 2003

(CE–1) 8 AM–12 NOON

Digital Microscopy and Analysis

This course gives a comprehensive introduction to modern digital microscopy for a quantitative analysis of biological samples. These methods are used to carry out morphometric measurements and to detect and quantify changes in cells and tissues resulting from toxic compounds, biochemical and physiological changes, aging, and learning.

This course will focus on the following:

- Acquisition of Digital Images
- Automated Image Analysis
- Fluorescent Microscopy
- 3D Microscopy
- Software Validation

(CE–2) 2 PM–6 PM

Development and Validation of Biomarkers of Risk or Effect

Contemporary toxicology bioassays are complemented with a range of mechanistic measurements. Biomarker research and development can provide critical data to link observations along this continuum into context with traditional morphologic, morphometric, and clinical pathology measurements. A discussion of biomarkers, their validation and development will be followed by three case studies. One will use environmental case studies as a mechanism to demonstrate validation and acceptance of biomarkers for regulatory risk assessment, and the other two will provide discussion on biomarkers of cardiovascular injury.

Plenary Lecture Monday, June 16, 2003

Dr. Carl Barrett, Scientific Director, Center for Cancer Research, National Cancer Institute, will provide the keynote address on "Future Directions in Cancer Research: Impact of Completion of the Human Genome."

Cancer/Human Genome/Pathology Monday, June 16, 2003

Discuss the impact of human genome data on toxicology, including genetic comparisons across species, the rat genome project, role of pharmacogenetics in treatment strategies, and cancer risk assessment.

Chair—Robert Sills, National Institute of Environmental Health Sciences
Samuel M. Cohen, University of Nebraska Medical Center
William E. Evans, St. Jude Children's Research Hospital
Howard J. Jacob, Medical College of Wisconsin and PhysioGenix

Individual Risk and Treatment Monday, June 16, 2003

Discuss SNP mapping of human disease alleles and the utility of SNP maps and integrated transcript data in efficacy/safety testing and in the development of treatment strategies.

Chair—Richard Miller, GlaxoSmithKline
Charles Flexner, Johns Hopkins University
Kevin Morgan, Aventis Pharmaceuticals
Allen Roses, GlaxoSmithKline

Animal Models of Carcinogenesis: Relevance to Human Disease Tuesday, June 17, 2003

Discuss the role of animal models of human cancer in investigating disease pathogenesis, testing prevention strategies and therapies, and assessing cancer risk.

Chair—Donna Kusewitt, The Ohio State University
Allan Balmain, University of California–San Francisco
Robert Cardiff, University of California–Davis
Joseph DeGeorge, Novartis Pharmaceuticals Corporation
Robert Maronpot, National Institute of Environmental Health Sciences
Joanne Schuh, Applied Veterinary Pathobiology

Molecular Pathology Wednesday, June 18, 2003

Talks will be given on the use of molecular profiling for understanding cancer pathogenesis, tumor suppressor gene knockout mice as models for human cancer genetic syndromes, gene expression patterns in human breast cancer and mouse mammary gland cancer models and toxicogenomics and carcinogenesis.

Chair—Jerrold M. Ward, National Cancer Institute
Richard D. Irwin, National Institute of Environmental Health Sciences
John W. Gillespie, National Cancer Institute
Jeffrey E. Green, National Cancer Institute

The Human Genome: Implications for Toxicologic Pathology and Carcinogenesis

March 20, 2003
Abstract
Electronic Submission
Deadline

Society of Toxicologic Pathology
22nd Annual Conference and Exhibition
June 15–19, 2003
Savannah, Georgia

Biomarkers and Mechanisms of Cancer Development

Wednesday, June 18, 2003

This session will include talks focused on the use of biomarkers in cancer discovery and diagnostics as a starting point for discussion on how to use this information to inform risk assessment on human cancer.

Chair—Donna Dambach, Bristol-Myers Squibb Company
Russell Cattley, Amgen, Inc.
Eugenia Floyd, Pfizer, Inc.
James MacGregor, U.S. Food and Drug Administration, NCTR
Chip Petricoin, U.S. Food and Drug Administration, CBER

Carcinogenesis and the Future of Cancer Risk Assessment

Thursday, June 19, 2003

The closing session will look into the future with discussions on the importance of protein and DNA adducts in risk assessment, signaling at the proliferation/apoptosis interface, the new EPA Cancer Risk Guidelines and the future of toxicology and risk assessment.

Chair—Thomas Goldsworthy, Integrated Laboratory Systems, Inc.
Myrtle Davis, Eli Lilly and Company
Harvey Mohrenweiser, Lawrence Livermore National Laboratory
R. Julian Preston, U.S. Environmental Protection Agency
James Swenberg, University of North Carolina

Exhibitor Theatre

Sunday, June 15, 12:00 PM – 2:00 PM

The STP Annual Meeting, in conjunction with the exhibitors, will present an Exhibitor Theatre on Sunday June 15. The theatre will be offered to the attendees as a complimentary workshop and will allow six exhibitors the opportunity to present information on new products in 20-minute sessions.

Exhibits Information

Where will you find an audience where 43% of the attendees work in management and are the final decision-makers for the organization? At the Society of Toxicologic Pathology Annual Meeting in Savannah, Georgia.

Visit **www.toxpath.org** to reserve a booth.

GRANT SPONSORSHIP OPPORTUNITIES SOCIETY OF TOXICOLOGIC PATHOLOGY 2003 ANNUAL MEETING

The Society of Toxicologic Pathology's goals can not be achieved without the generous contributions made by sponsors. The Society has five different sponsorship levels available to interested organizations. **Diamond Sponsor** ($15,000 and above); **Emerald Sponsor** ($10,000 – $14,999); **Opal Sponsor** ($7,500 – $9,999); **Ruby Sponsor** ($5,000 – $7,499), **Sapphire Sponsor** ($2,500 – $4,999), and **Tanzanite Sponsor** ($1,000 – $2,499). Sponsors will receive recognition before, during, and after the Annual Meeting through postings on the STP Web site, listings in *Preliminary Program* and newsletters, on-site signage, and announcements. Specific listing of sponsor's benefits can be found on the STP Web site. If you and/or your company are interested in being a 2003 STP Annual Meeting sponsor, please contact STP Headquarters at (703) 438-7508.

Annual Symposium Grant Sponsors Contributions will receive acknowledgment at the following activities:

- Conference Refreshments Continuing
- Education Course Refreshments
- Educational Program Refreshments
- President's Reception
- Student Registration
- Welcoming Reception

Annual Business Meeting Announcement of Awards:

- Student Travel Award
- Young Faculty Development Grant
- Young Investigator Award

An NTP sponsored Satellite Symposium will precede the meeting on Saturday, June 14 and will consist of *An Exercise in Peer Review: The Pathology Working Group* organized by Dr. Robert R. Maronpot.

To register for the STP Annual Meeting, the NTP Satellite Symposium, and to reserve an exhibit booth, visit

www.toxpath.org

SCIENTIFIC AND REGULATORY POLICY COMMITTEE (SRPC) REPORT

continued from page 3

pathology, and digital imaging. Separate subcommittees are being formed to address each of these areas. The final draft of the histopathology data collection and audit trail position document has been completed and will be put on-line at the STP Web site for comment from the membership by the end of the 2002.

The standardized tissue list will be published in *ToxPath* in early 2003.

A part 11 subcommittee has been formed to provide comments to the FDA Draft Guidance on Part 11, due Dec 4, 2002. A draft document has been prepared.

A subcommittee for addressing issues around sectioning large animal brains has been formed and has completed a first draft document. The document should be ready for review by the membership by early 2003.

Completed topics: Peto analysis, testis evaluation, and comments on the immunotoxicology guidelines. Other areas being discussed as possible topics for subcommittee review are determining cause of death for toxicity studies, the use of transgenic mice for carcinogenicity testing, the use of step sectioning for evaluation of tumor responses, and determining NOEL vs. NOAEL from histopathology data.

The complete article is available on the Web site.

STUDENT TRAVEL AWARD

Purpose

Travel Awards are available to Graduate Students for participation in the 22nd Annual Symposium of the Society of Toxicologic Pathology to be held in Savannah, Georgia, June 15–19, 2003.

continued on page 8

EXTERNAL AFFAIRS COMMITTEE

by George L. Foley

The nine STP liaisons have worked to improve communications between the Executive Committee of the STP and our allied societies. We have a new liaison for the American College of Toxicology with Laura Morton replacing Merrill Osheroff. Attached are summaries of the fall 2002 liaison reports. Complete reports will be posted on the STP Web site.

Summaries of liaison reports follow:

Am Coll Toxicol (Laura Morton): The STP sponsored a symposium of Current issues in Toxicologic Pathology at the 23rd ACT Annual Meeting in Hershey, Pennsylvania on November 11. Topics included STP testis guidelines, vasculitis, endothelin receptor antagonist injury, and ocular toxicologic pathology. There are plans to include STP sponsored events for the 24th ACT Annual Meeting next year.

ACVP (Keith Harris): The ACVP recently had a council meeting to discuss the ACVP strategic plan, ACVP-STP employer/training survey, 2002 exam results, electronic publication of the journal *Veterinary Pathology* and the issue of denied approval of a Toxicologic Pathology subspecialty.

Croplife America (David Eisenbrandt): The CLA's Human Health & Risk Assessment Round Table (HART) are dealing with issues ranging from cancer risk assessment, developmental neurotoxicology studies, endocrine disruption test methodologies, inhalation studies, immunotoxicology, and developmental thyroid toxicology.

ILSI (Charlotte Keenan): The Emerging Issues Committee is a mechanism to assist ILSI HESI in identifying emerging scientific issues. Issues range from agricultural chemical safety assessments, cardiovascular safety issues, and biomarkers of toxicity. A more complete list is included in the whole liaison report on the STP Web site. A list of active ILSI Technical Committees is also included on the complete liaison report. There will be an ILSI seminar on "Emerging technologies form microscopy to non-invasive imaging" on December 7, 2002 in conjunction with the ACVP meeting.

NTP (Ron Herbert): The Technical Report Peer Review Subcommittee met in September 2002 to review 5 chronic rodent studies and 2 transgenic mouse studies. Reviews of the draft report are included on the liaison report posted on the Web site. The NTP will co-host a satellite symposium at the 2003 STP Annual Meeting on "An exercise in peer review: the pathology working group." The NTP's toxicogenomic program will apply differential gene expression and proteinomic assessments to NTP studies to explore these methodologies. A ToxPath data group has been formed to help interpret and present the gene expression data.

PhRMA (Darrell Tuomari): PhRMA has been dealing with a number of issues including 21 CRF Part 11, OECD-GLP's, and genotoxicity. A complete list of PhRMA issues is included in the full liaison report on the STP Web site.

SOT (Darlene Dixon): The 2003 SOT Annual Meeting will be held in Salt Lake City, Utah and there are many topics of overlapping interest to STP. As of January 2003, SOT will no longer sponsor *Toxicology and Applied Pharmacology*, leaving *Toxicological Sciences* as the SOT's official journal.

SQA (Lynda Lanning): the Society of Quality Assurance had their annual meeting in October 2002. STP sponsored a 90-minute session entitled "Toxicologic Pathology: Current practices and new technologies." The STP also sponsored a poster at the SQA meeting that described the STP mission and facts on membership. There is an opportunity for STP to sponsor a symposium at the 2003 meeting with an early 2003 deadline for topic and list of speakers.

STP STRATEGIC PLAN PROGRESS REPORT

This fall, the Executive Council held a strategic planning session, during which a vision statement and mission statement were formulated. The intent of these statements is to define who we are and what we do (Mission) and to provide a statement (Vision) regarding what we would like to become in the future. Recognizing that these statements are a work in progress, the Executive Council is soliciting input from the membership regarding the wording of these statements.

Draft Vision Statement: To be recognized as the global authoritative scours of interpretation of toxicologic pathology.

Draft Mission Statement: We identify, interpreted biological responses to xenobiotics to benefit human and animal health.

The Executive Council also identified six categories of audiences that the Society would like to reach as part of its activities. Again, your council requests that you as a member consider whether these categories are appropriate and whether omissions have been made.

Audiences: Membership, Academia, Industry, General Public, Regulatory Agencies, and other Professionals in Risk Assessment.

The process for developing the new strategic plan is as follows: A subcommittee comprised of Drs. Robertson, Gillett, Rousseaux, Ochoa and Haschek-Hock and Ms. Wilson will review and incorporate members' comments into a final draft of a vision statement and a mission statement. In addition, the subcommittee will begin drafting goals and strategic objectives for the Society. As these items receive Executive Council approval, you will be asked again to comment. Please keep the STP Web site bookmarked, as updates to the strategic plan will be posted on this site. A good strategic plan requires your input. STP Web site address: **www.toxpath.org**.

FUNDRAISING COMMITTEE REPORT

The Fundraising Committee is in the process of contacting potential sponsors for the 2003 Annual Meeting to be held in Savannah, Georgia. In addition, the Committee is also contacting organizations to renew or establish new Organizational Membership within the Society. It's through the continued support of organizations that STP is able to achieve its mission and goals to play an intricate role in fostering training and recognition of toxicologic pathologists.

The Fundraising Committee needs the support of all Society members to solicit funds for the Society. General Organizational Membership dues finance the general administration of the Society and also contribute to the reduced Annual Meeting membership registration fees.

A list of Organizational Membership Benefits are available on the STP Web site. If you have any questions or recommendations, please contact STP Headquarters at (703) 438-7508.



STUDENT TRAVEL AWARDS

continued from page 6

Listed below are the specifics for the 2003 Student Travel Awards competition:

- Recipients will be awarded a grant to defray registration, travel, and lodging costs associated with attendance at the Annual Symposium.
- Recipients will be honored at an awards ceremony during the business meeting.

Eligibility

- Nominees must currently be enrolled in a full-time veterinary medical or medical graduate degree or residency program in pathology/toxicology and have a demonstrated interest in toxicologic pathology. Nomination of candidates who have recently completed (within 12 months) a graduate and/or residency program in toxicologic pathology will also be accepted.

Nomination Procedure

- The student's faculty advisor must submit a letter of nomination summarizing qualifications of candidate and a *curriculum vitae* of candidate with a statement of career goals in toxicologic pathology.
- Submission of an abstract for a poster presentation at the Annual Meeting in the area of toxicologic pathology is encouraged but not required.

Deadline

- Nomination materials should be submitted by March 14, 2003. Winners will be notified shortly thereafter.

Mailing Address

- Send all nominations to the Society of Toxicologic Pathology, 1767 Business Center Drive, Suite 302, Reston, VA 20190.

EXECUTIVE COUNCIL (EC) OCTOBER 2002 HIGHLIGHTS

The Executive Council approved the following items:

- The policy that the Annual Meeting should be a break-even endeavor that benefits the overall membership.
- The Symposium Committee's recommendation that the theme for the 2004 Annual Meeting should be Hepatotoxicity, and Special Senses will be the topic of a future continuing education course.
- The Membership Committee's recommendations for new members. The list can be found on page 2.
- $4,000 for the printing of the 2002 Annual Meeting journal supplement. The EC complimented Dr. Maronpot on raising the additional funds for the publication via the 2002 exhibit companies.

The EC approved the following appointments for liaisons:

Laura Morton, American College of Toxicology
Keith Harris, American College of Veterinary Pathology
David Eisenbrandt, CropLife America